Approved indication: Eovist is FDA-approved for intravenous use in MRI of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.

Off-label uses and evidence: Radiologists also use Eovist-enhanced MRI to help distinguish focal nodular hyperplasia from hepatocellular adenoma, to aid hepatocellular carcinoma surveillance and surgical planning, to evaluate liver lesions after transplantation, and for certain biliary studies (such as suspected bile leaks or strictures); these uses are supported mainly by observational studies, specialty-center experience, and comparative imaging studies rather than large randomized trials.

Efficacy expectations and comparison: Eovist begins improving liver MRI images within seconds to minutes of injection, with additional liver-specific (hepatobiliary) contrast typically seen around 20 minutes, increasing sensitivity for many focal liver lesions compared with non-contrast MRI and often outperforming standard extracellular gadolinium agents for detecting and characterizing small metastases and focal nodular hyperplasia, though early arterial-phase images can be more susceptible to motion artifacts.

Typical dosing and how it is given: For adults (and for most older pediatric patients when used), the recommended dose is a single 0.1 mL/kg intravenous bolus injection of undiluted Eovist (0.025 mmol/kg), administered at about 1–2 mL per second through a peripheral vein immediately before or during the liver MRI and followed by a normal saline flush; it is given only by trained healthcare professionals, and there are no specific requirements regarding food, drink, or time of day.

Special dosing and administration instructions: Dose adjustment is usually not needed for age alone, but Eovist should be used cautiously, if at all, in patients with severe kidney impairment, acute kidney injury, or combined severe kidney and liver disease, and it must not be injected into the spinal canal (intrathecal) or into muscle and should not be mixed in the same IV line simultaneously with other medications.

Missed dose and overdose guidance: Because Eovist is given as a one-time injection during a scheduled MRI visit, a missed dose typically means the scan will be rescheduled; overdose is uncommon but, if it occurs, patients are monitored and treated supportively in a medical setting, and in those with significant kidney dysfunction who are already on dialysis, hemodialysis can help remove gadolinium from the body.

Common side effects: The most frequent side effects are nausea, headache, a feeling of warmth or flushing, dizziness, and back pain, each occurring in roughly 0.5–1% of patients; they are usually mild, begin during or shortly after the injection, and resolve on their own.

Serious or rare adverse effects: Rarely, patients can experience severe allergic or anaphylactoid reactions (such as trouble breathing, swelling of the face or throat, chest tightness, or shock) that require immediate emergency treatment; in people with severe kidney impairment or acute kidney injury, gadolinium-based contrast agents like Eovist can cause nephrogenic systemic fibrosis, a serious condition with thickening and hardening of the skin and internal organs, and accidental extravasation of the drug outside the vein can sometimes lead to local tissue injury.

Warnings and precautions (pregnancy, breastfeeding, age, kidney/liver disease): Eovist should be avoided or used only when essential in patients with severe kidney dysfunction or hepatorenal syndrome, and with caution in those who have had a prior severe reaction to gadolinium contrast or have severe liver failure; in pregnancy, it is generally reserved for situations where MRI with contrast is essential and cannot be delayed, and breastfeeding women may choose to continue nursing normally or to pump and discard milk for up to about 10 hours after the injection to minimize infant exposure; safety and effectiveness are not established in premature infants, and use in older children is based on limited clinical data.

Overall safety compared with similar drugs: At the recommended single dose, the overall rate and pattern of side effects with Eovist are similar to other gadolinium-based MRI contrast agents, but, like the rest of this class, it carries risks of gadolinium retention in the body and of nephrogenic systemic fibrosis in susceptible patients, so it is used when the added diagnostic value of liver-specific imaging is important.

Reporting side effects and safety information: Side effects can be reported to the care team, to the manufacturer, or to the FDA’s MedWatch program, and up-to-date safety warnings and guidance are provided in the current prescribing information and on regulatory and manufacturer information resources.

Drug, supplement, and food interactions: No major, specific drug–drug or supplement interactions are known for Eovist, and food does not meaningfully affect how it works, but patients should always inform their care team about all prescription medicines, over-the-counter products, and supplements they take so the radiologist can coordinate care and avoid unnecessary exposure to multiple gadolinium-based contrast agents.

Alcohol, other contrast agents, and procedures: Moderate alcohol intake does not significantly change the effect of Eovist, but other sedating medicines, anesthetics, or contrast agents used around the time of MRI should be coordinated and monitored by the healthcare team, and Eovist must never be administered into the spinal canal or mixed in the same IV line at the same time with other drugs unless specifically directed by protocol.

Precautions and conditions affecting safety: Severe chronic kidney disease, acute kidney injury, or hepatorenal syndrome markedly increase the risk of nephrogenic systemic fibrosis with gadolinium contrast, and serious liver failure, very high bilirubin, or high iron stores can reduce the quality of liver images; a history of severe allergic reaction to gadolinium contrast, uncontrolled asthma, pregnancy, and very young age (especially premature infants) all warrant extra caution and may lead clinicians to consider alternative imaging strategies.

Monitoring needs and test interference: Before giving Eovist, patients at risk for kidney disease (for example, older adults or those with diabetes or hypertension) are often screened by history and, when needed, blood tests of kidney function; during and immediately after the injection, patients are observed for allergic reactions or injection-site problems, and clinicians are aware that Eovist can temporarily interfere with some serum iron tests for about 24 hours after administration.

Q: What is Eovist used for?
A: Eovist is an intravenous contrast agent used during MRI scans of the liver to help radiologists detect and better characterize focal liver lesions such as tumors, cysts, or scars.

Q: How long does Eovist stay in my body?
A: In people with normal kidney and liver function, most of the contrast is eliminated through urine and bile within hours to a few days, although very small amounts of gadolinium can remain in body tissues for longer without known short-term effects in most patients.

Q: Is Eovist safe if I have kidney problems?
A: Eovist and other gadolinium-based contrast agents can increase the risk of nephrogenic systemic fibrosis in people with severe kidney impairment or acute kidney injury, so your kidney function will be reviewed and the scan may be postponed, changed, or done with extra precautions if your kidneys are not working well.

Q: Can I receive Eovist if I am pregnant or breastfeeding?
A: During pregnancy, Eovist is generally used only when MRI with contrast is essential and cannot be delayed, while breastfeeding mothers can usually continue nursing and may choose, if they wish, to pump and discard milk for a short time (up to about 10 hours) after the injection to further reduce any exposure to the baby.

Q: Will I feel anything when Eovist is injected?
A: Many people feel only the brief needle stick, but some notice a warm sensation, metallic taste, or mild nausea for a short time during or right after the injection, and you should immediately tell the staff if you feel short of breath, itchy, lightheaded, or unwell.